

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q91454

Yoshiji TAKEMOTO

Appln. No.: 10/562,579

Group Art Unit: 1625

Confirmation No.: 7875

Examiner: Unknown

Filed: December 27, 2005

For: ASYMMETRIC UREA COMPOUND AND PROCESS FOR PRODUCING
ASYMMETRIC COMPOUND BY ASYMMETRIC CONJUGATE ADDITION
REACTION WITH THE SAME AS CATALYST

INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. De Costa, B.R. et al., "A Practical Synthesis, Optical Resolution and Determination of Absolute Configuration of Enantiomerically Pure 1S,2R-(+)- and 1R,2S-(-)-CIS-2-(1-Pyrrolikinyl)Cyclohexyl Amines: Important Precursors for a new class of Sigma-Receptor Ligands and Anticonvulsant Drugs", Heterocycles, Vol. 31, No. 10, (1990), pp. 1837-1846.

2. EP 0 903 349 A2, published March 24, 1999 to Hoffmann-La Roche AG.
3. WO 03/045917 A2, published June 5, 2003 to Hoffmann-La Roche AG.
4. WO 03/022799 A, published March 20, 2003 to Hoffmann-La Roche AG.
5. Pandey, B.R. et al., "Interrelationship between anticonvulsant and enzyme inhibitory properties of N-methyl-N-2-[1-(1-arylthiocarbamido)]cyclopentyl nitrobenzamides", Pharmacological Research Communications, Vol. 13, No. 1, (1981), pp. 65-74.
6. WO 03/045393 A1, published June 5, 2003 to Hoffmann-La Roche AG.
7. Southwick, P.L. et al., "The Stereochemistry of Conjugate Additions. A Study of the Addition of Amines to (2-Nitropropenyl)-Benzene", Journal of the American Chemical Society, Vol. 79, (1957), pp. 6222-6229.
8. Barnes, D.M. et al., "Development of a Catalytic Enantioselective Conjugate Addition of 1, 3-Dicarbonyl Compounds to Nitroalkenes for the Synthesis of Endothelin-A Antagonist ABT-546. Scope, Mechanism, and Further Application to the Synthesis of the Antidepressant Rolipram", Journal of the American Chemical Society, Vol. 122, No. 44, (2002), pp. 13097-13105.
9. Ji, J. et al., "Catalytic Enantioselective Conjugate Addition of 1, 3-Dicarbonyl Compounds to Nitroalkenes", Journal of the American Chemical Society, Vol. 121, No. 43, (1999), pp. 10215-10216.

One copy of each of the listed documents is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after


filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Applicant encloses herewith a copy of a corresponding Supplementary Partial European Search Report citing such documents and indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,


John T. Callahan
Registration No. 32,607

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: October 22, 2007